The Hong Kong group has acquired the Longevity AI and aging clock specialist Deep Longevity.
In a move that cements their expansion into the emerging field of AI and Longevity medicine (while strengthening the shareholder mix by adding experienced Longevity and wellness biotechnology investors and entrepreneurs) Regent Pacific has successfully completed its previously-announced acquisition of Deep Longevity.
Longevity.Technology: Longevity conjures up ideas of lifespans and decades, but Deep Longevity has successfully demonstrated that speed is important too. Insilico Medicine announced that its spin-out Deep Longevity had exited stealth just five months ago, and it came out of the gate strong, having secured a collaboration with Human Longevity Inc to deploy an extensive range of AI-powered aging clocks.
Originally backed by venture capitalists specialising in biotechnology, Longevity and AI, including ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC and the co-founder of Oculus, Michael Antonov, Deep Longevity’s pace hasn’t let up, either, with news of its biometric-crunching Young.AI app, a collaboration with Longenesis and a new Longevity Medicine for Physicians course following hot on the heels of its acquisition by Regent Pacific. It is exciting to see the speed and breadth of their accomplishments and Deep Longevity makes a worthy jewel in the Regent’s crown.
Pursuant to the Share Purchase Agreements, Regent Pacific has acquired all the issued and outstanding securities in Deep Longevity Inc, at the total consideration of US$3.79 million, which was satisfied by the issue and allotment by the Company of an aggregate of 422.69 million consideration shares.
Regent Pacific is a Hong Kong-based diversified investment group based in Hong Kong, specialising in healthcare, wellness and life sciences investments. The group has returned approximately US$298 million to shareholders in the 23 years of financial reporting since its initial public offering in May 1997.
Jamie Gibson, Chief Executive Officer of Regent Pacific, said, “We are delighted to have completed the acquisition of Deep Longevity as it signifies a major milestone in our development in becoming a global end-to-end longevity and wellness biotechnology company.
“Deep Longevity … aspires to be a leader in the field of machine learning for personalised preventative healthcare and longevity interventions.”
“Deep Longevity provides users with the most efficient, reliable and useful aging and longevity clocks that can help people live better, longer and healthier lives, with its patented DNA deep methylation clock being the most accurate in its field.
Deep Longevity possesses first-mover advantage in Asia, has state-of-the-art technology driven by AI and aspires to be a leader in the field of machine learning for personalised preventative healthcare and longevity interventions.
“The acquisition will allow Regent Pacific to expand into the global wellness market that was estimated to be over US$4.20 trillion in 2017. Deep Longevity’s sophisticated AI system is uniquely able to track the rate of human aging and evaluate the effectiveness of longevity interventions.”
Alex Zhavoronkov, PhD, founder and CEO of Deep Longevity, said: “We are pleased to reach this important milestone for Deep Longevity. As part of Regent Pacific, we are excited to add our scientists and experts to the Group which aim to serve the longevity biotechnology industry as well as the health and life insurance industries and become the ultimate instrument to hedge the longevity risk.”